pharma · Lymphoma · Primary immune thrombocytopenia (ITP)
Hutchmed Europe B.V.
Hutchmed Europe is a pharma organization headquartered in EU. Primary therapeutic focus areas include Lymphoma, Primary immune thrombocytopenia (ITP). NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0
Phase 1 · other · Lymphoma
HMPL-523 is an investigational oncology agent being developed by Hutchmed Europe B.V. for the treatment of relapsed or refractory lymphoma. The program is currently in Phase I development, evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with this hematologic malignancy. The trial
Internal code 2018-523-00US1
HMPL-523 is an investigational oncology agent being developed by Hutchmed Europe B.V. for the treatment of relapsed or refractory lymphoma. The program is currently in Phase I development, evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with this hematologic malignancy. The trial is open-label and designed to establish a tolerable dose and initial clinical activity profile in a patient population with limited treatment options after prior therapy failure.
The sponsor's strategy focuses on early-stage safety and dose-escalation characterization in a disease area with multiple approved therapies but continued unmet need for patients who develop resistance to standard treatments. The program remains active in clinical development with an NCT identifier of 2024-515123-11-00. Mechanism of action, specific molecular target, and detailed pharmacological properties have not yet been disclosed in available sources. The oral route of administration has been identified for the investigational agent.
Key regulatory and clinical milestones remain to be disclosed. Peak sales projections and consensus analyst positioning are not yet available. The competitive landscape includes multiple approved agents such as ibrutinib, brentuximab vedotin, and temsirolimus, as well as several programs in Phase III development targeting similar patient populations.
Relapsed or refractory lymphoma represents a significant unmet medical need despite the availability of multiple approved therapies. Patients who fail initial treatment or develop resistance to standard agents face limited options and poor prognosis, creating clinical urgency for new therapeutic approaches. The lymphoma market encompasses both Hodgkin and non-Hodgkin subtypes, representing a substantial patient population globally with heterogeneous disease biology and variable treatment responses.
HMPL-523 enters a competitive but active development space where multiple mechanisms of action are being pursued, including Bruton tyrosine kinase inhibitors (ibrutinib), antibody-drug conjugates (brentuximab vedotin), and mTOR inhibitors (temsirolimus). The Phase I program will establish whether this agent offers a differentiated safety or efficacy profile compared to existing options. Commercial significance depends on the emerging safety data, preliminary efficacy signals, and the agent's positioning relative to approved and late-stage competitors.
Hutchmed Europe's development of HMPL-523 reflects the continued investment in lymphoma therapeutics despite market saturation. The oral route of administration, if confirmed as convenient and well-tolerated, could offer practical advantages over intravenous competitors. Early Phase I data will determine whether advancement to Phase II is warranted and whether the agent warrants further investment in this competitive indication.
HMPL-523 is an investigational small-molecule oncology agent administered orally. The specific mechanism of action, molecular target, and drug class have not yet been disclosed in available sources. The agent is being evaluated as a monotherapy in relapsed or refractory lymphoma patients.
Also known as: lymphoma (Hodgkin and non-Hodgkin), lymphoma (Hodgkin's and non-Hodgkin's), lymphoma, malignant, lymphomatous, malignant lymphoma, MLYM
A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.
ClinicalTrials.gov lists 16 registered studies for Lymphoma, Hodgkin (AACT aggregate).
Phase breakdown: NA (10), PHASE1 (3), PHASE2 (3)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0005062), Orphanet — lymphoma, NCT00026208, NCT00578461, NCT01459224, NCT02996773, NCT03117036, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase I Open-Label Safety and Efficacy Study
Ongoing Phase I evaluation of HMPL-523 for safety, tolerability, pharmacokinetics, and preliminary efficacy in relapsed or refractory lymphoma patients (NCT 2024-515123-11-00).
HMPL-523 enters a competitive lymphoma therapeutics landscape with multiple approved agents and several programs in late-stage development. Approved competitors include ibrutinib (AbbVie Deutschland), a Bruton tyrosine kinase inhibitor widely used in lymphoid malignancies; brentuximab vedotin (Takeda), an antibody-drug conjugate targeting CD30; temsirolimus (Pfizer), an mTOR inhibitor; etoposide (Xiyuan Hospital), a topoisomerase II inhibitor; and denileukin difitox (Ligand Pharmaceuticals), a recombinant fusion protein.
Late-stage competitors in Phase III development include pirtobrutinib and ibrutinib (Wuhan Createrna), E7777 (Citius Oncology), and combination regimens including rituximab, gemcitabine, and oxaliplatin (Hoffmann-La Roche). Karyopharm Therapeutics is advancing a multi-agent Phase III program. The competitive positioning of HMPL-523 will depend on its emerging safety profile, preliminary efficacy signals, and differentiation relative to these established and investigational agents. The oral route of administration may offer practical advantages over intravenous competitors if tolerability is favorable.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| Etoposide | Xiyuan Hospital of China Academy of Chinese Medical Sciences | small_molecule | approved |
| Ibrutinib | AbbVie Deutschland GmbH & Co. KG | small_molecule | approved |
| Brentuximab vedotin | Takeda | small_molecule | approved |
| crizotinib | Xiyuan Hospital of China Academy of Chinese Medical Sciences | small_molecule | approved |
| ONTAK (denileukin difitox, DAB389IL-2) | LIGAND PHARMACEUTICALS INC | small_molecule | approved |
| temsirolimus | Pfizer | small_molecule | approved |
| AMOXICILLIN TRIHYDRATE, SULFAMETHOXAZOLE AND TRIMETHOPRIM , LEVOFLOXACIN, AMOXICILLIN , AZITHROMYCIN, AZITHROMYCIN , IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., LEVOFLOXACIN | Pari Pharma GmbH | small_molecule | phase_3 |
| Ondansetron Aurobindo 8 mg Filmtabletten, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Dexametazona Krka 4 mg comprimate, EMEND 125 mg+80 mg hard capsules, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, G | Karyopharm Therapeutics Inc | small_molecule | phase_3 |
| PIRTOBRUTINIB, IBRUTINIB, PIRTOBRUTINIB, IBRUTINIB | Wuhan Createrna Science and Technology Co., Ltd | small_molecule | phase_3 |
| E7777 9 mcg/kg | CITIUS ONCOLOGY, INC. | small_molecule | phase_3 |
| MabThera 500 mg concentrate for solution for infusion, Polivy 140 mg powder for concentrate for solution for infusion., GEMCITABINE , OXALIPLATIN | Hoffmann-La Roche | small_molecule | phase_3 |
| ZOLEDRONIC ACID | — | Farnesyl diphosphate synthase inhibitor | Approved |
| ZANUBRUTINIB | — | Tyrosine-protein kinase BTK inhibitor | Approved |
| VORINOSTAT | — | Histone deacetylase 1 inhibitor | Approved |
| VINBLASTINE SULFATE | — | Tubulin inhibitor | Approved |
| VENETOCLAX | — | Apoptosis regulator Bcl-2 inhibitor | Approved |
| UMBRALISIB TOSYLATE | — | Tyrosine-protein kinase ABL inhibitor | Approved |
| TISAGENLECLEUCEL | — | B-lymphocyte antigen CD19 binding agent | Approved |
| THALIDOMIDE | — | CRL4(CRBN) E3 ubiquitin ligase inhibitor | Approved |
| TECLISTAMAB | — | Tumor necrosis factor receptor superfamily member 17 binding agent | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
HMPL-523 regulatory status by jurisdiction:
The program is identified by NCT identifier 2024-515123-11-00 and internal code 2018-523-00US1. Specific FDA guidance letters, breakthrough therapy designations, fast-track status, or accelerated approval pathways have not been disclosed. Expected timelines for regulatory milestones, including Phase II initiation or filing dates, remain to be disclosed.
HMPL-523 is an investigational oral small-molecule oncology agent being developed by Hutchmed Europe B.V. for the treatment of relapsed or refractory lymphoma, a blood cancer that has failed to respond to or has recurred after prior therapy.
No, HMPL-523 is not approved. The program is currently in Phase I clinical development, which is the earliest stage of human testing focused on safety and tolerability.
The specific mechanism of action has not yet been disclosed by the sponsor. This information is expected to be revealed as the clinical program advances.
HMPL-523 is being developed by Hutchmed Europe B.V., a European pharmaceutical company. No development partner has been disclosed.
The Phase I study is identified by NCT identifier 2024-515123-11-00 and internal code 2018-523-00US1.
HMPL-523 is administered orally, which may offer convenience advantages compared to intravenous lymphoma therapies.
The Phase I trial enrolls patients with relapsed or refractory lymphoma, meaning patients whose disease has not responded to or has recurred after prior treatment.
The Phase I study is evaluating safety, tolerability, pharmacokinetics (how the body processes the drug), and preliminary efficacy of HMPL-523 in lymphoma patients.
Approved competitors include ibrutinib, brentuximab vedotin, and temsirolimus. Late-stage competitors in Phase III include pirtobrutinib, E7777, and rituximab-based combinations.
No approval timeline has been disclosed. The program is in Phase I, and typical development timelines for oncology drugs range from 5-10+ years from Phase I initiation to potential approval.
Patients with relapsed or refractory lymphoma have limited treatment options and poor prognosis after failing standard therapies, creating clinical urgency for new therapeutic approaches.
Expedited regulatory designations such as breakthrough therapy, fast-track status, or accelerated approval pathways have not been disclosed.
The specific molecular target has not yet been disclosed by the sponsor and is expected to be revealed as development progresses.
The Phase I trial is evaluating HMPL-523 as a monotherapy in relapsed or refractory lymphoma patients.
HMPL-523 is in Phase I development with Hutchmed Europe B.V. as sponsor; specific regulatory agency interactions and pathways have not been disclosed.
Commercial significance depends on emerging Phase I safety data, preliminary efficacy signals, and differentiation relative to approved and late-stage competitors; peak sales projections have not been disclosed.
2018-523-00US1 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Hutchmed Europe's advancement of HMPL-523 reflects continued confidence in the lymphoma market despite competitive saturation. The oral formulation and early-stage safety focus suggest a strategy to identify a differentiated safety or convenience profile. Phase I data will be critical in determining whether the agent merits Phase II investment in this crowded indication.
Competitive Implications: HMPL-523 must demonstrate clear advantages over approved agents (ibrutinib, brentuximab vedotin, temsirolimus) and late-stage competitors (pirtobrutinib, E7777) to justify market entry. The lack of disclosed mechanism of action limits competitive positioning assessment; disclosure of target and MOA will be essential for investor and clinical community evaluation.
Future Catalysts: Phase I safety and preliminary efficacy data release; dose-escalation completion; Phase II initiation decision; disclosure of mechanism of action and molecular target; regulatory feedback on development pathway; potential biomarker or patient selection strategies.
Expected Milestones: Phase I completion and data presentation; Phase II trial design and initiation; potential regulatory meetings with FDA or EMA to confirm development strategy; competitive positioning relative to emerging Phase III data from pirtobrutinib and other agents.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.